COMPANY

Innovative Cardiovascular Solutions

Profile checked Oct 10, 2026

Keywords: Aortic Valve Replacement Aortic Valve Disease AORTIC VALVE DISEASES Aortic Valve Stenosis and/or Insufficiency Aortic Valve Regurgitation Aortic Valve Stenosis Aortic Valve Insufficiency EMBLOK™ Embolic Protection System EMBLOK filter

3Trials (company is sponsor)

Timeline

Oct 21, 2025 Trial start Not phased (device or behavioral study): Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR source ↗
Oct 17, 2023 Trial start Not phased (device or behavioral study): Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR source ↗
Mar 8, 2017 Trial start Not phased (device or behavioral study): European Study Evaluating the EMBLOK Embolic Protection System During TAVR source ↗

Upcoming milestones

Jan 31, 2027 (ESTIMATED) · Not phased · Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR · NCT07129421

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07129421	Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR	Not phased (device or behavioral study)	Not yet recruiting	Oct 21, 2025	Jan 31, 2027 (estimated)
NCT05295628	Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR	Not phased (device or behavioral study)	Active, not recruiting	Oct 17, 2023	May 6, 2025 (actual)
NCT03130491	European Study Evaluating the EMBLOK Embolic Protection System During TAVR	Not phased (device or behavioral study)	Completed	Mar 8, 2017	Nov 1, 2021 (actual)